is our nature

Discover our research

Our commitment to research, development and the production of biopharmaceutical products.

Dompé is active in Primary Care, producing prescription drugs and over the counter (OTC) medicines, dietary supplements, medical devices and cosmetics.

We are also committed to finding innovative solutions for the treatment of rare diseases where a new therapy can provide a significant improvement over the current standard of care.

Dompé’s Cenegermin Nerve Growth Factor-based therapy was awarded Breakthrough Therapy designation by the US Food and Drug Administration (FDA) and marketing authorized by the European Medicines Agency (EMA) in July 2017, by the FDA in August 2018 and by the NMPA in China in August 2020.


Dompé farmaceutici was founded in 1940, with its roots in 19th century pharmaceutical science.


Every year, we reinvest 15% of our annual turnover in Research & Development (R&D).

300 centres

Our global network of over 300 centers supports our research

Find out about us

Research, development and production contributing to innovation

Alongside our manufacturing activities, our hub in L’Aquila also accommodates a number of research facilities covering the whole Drug Discovery process for small molecules and biotech drugs, from the early stage to clinical development and patient administration.

Discover our production hub

8 production lines

7 synthesis, 1 biotech

60 million

manufactured packages per year

CDMO facility

synthesis and biotech

27 clinical trials

over 200 patients

Dompé farmaceutici S.p.A. Single shareholder company / Share capital € 50.000.000,00
REA MI 289519 - A registered company in Milan, Italy / Tax code and VAT number IT00791570153